WHAT’S NEW WITH DR. FUNGUS

We initially launched Doctor Fungus Website with the URL (http://msgercdoctorfungus.com). This Spring 2018 we have obtained the domain name: www.drfungus.org. Both URLs will gain entry to the DoctorFungus website.

The compilation of mycology information contained in the site includes combinations of older content from the earlier Doctor Fungus site, and is now paired with emerging updates. New material is being continuously revised and updated by key opinion leaders in medical mycology and the Doctor Fungus Editorial Team. We are also featuring Doctor Fungus “Case of the Month”, and we aim for this to be a dynamic learning site.

We are also featuring the distinguished lectures from the 2016 Biennial Meeting and plan to also feature those from the 2018 meeting in Big Sky.

This is your site. If you are interested in submitting cases of the month, reviewing and updating content, or to ask questions, please contact me at grthompson@ucdavis.edu

-George Thompson, MD

DOCTOR FUNGUS CASE OF THE MONTH

What was the most interesting Medical Mycology case you have seen in the hospital or in clinic?

Please take the lead in writing up those cases using a format adopted from the Gorgas Course in Tropical Medicine. We will feature these monthly on the Doctor Fungus website. The format for submissions will be:

- HPI
- PMH
- PE
- Labs
- Imaging
- Microbiology
- Diagnosis
- Clinical Course
- Discussion
- Nomenclature
- Epidemiology
- Diagnosis and Treatment
- Outcomes
- References
- Associated jpeg images important!

All you have to do is fill in the blanks in word and include your jpeg images. This is also an excellent opportunity for fellows-in-training. Please submit cases and images to Peter G. Pappas, MD at ppappas@uabmc.edu or Carolynn Jones at jones.5342@osu.edu

www.drfungus.org
Dear Colleagues,

It is hard to believe that we are approaching the 2nd Biennial Meeting “Clinical Mycology Today” and we hope that you have made plans to attend. We have an exciting agenda featuring a series of plenary talks that fall into 4 broad categories (e.g., candidiasis, invasive aspergillosis, endemic mycoses, cryptococcosis), and these sessions are followed by panel and audience interactive discussions. This was a most fruitful aspect of our 2016 meeting, serving to identify through in-depth open discussion some of the key unmet needs, new research questions and shared knowledge which helped to shape a clinical research agenda for the next two years. We are very grateful for the support we have received for the 2018 Biennial MSGERC meeting from many of our partnering biotech companies, and we look forward to their interactive participation in the meeting.

Together, we champion evidence-based diagnoses, prevention, treatment and management of invasive fungal infection through our mission of Education, Research, Scholarship and Advocacy.

During our 2018 meeting, John Perfect, MD will move into his elected Board position as MSGERC President and I will move to the Immediate Past-President Board position. We will be having elections for Secretary and several Members at Large which will be solicited by email followed by vote of our members, prior to the meeting in September. We will announce those newly elected positions at the meeting.

Our 2017-18 clinical research advisory activities included work with T2 Biosystems, Scynexis, Cidara, Mayne and Vical. Newly launched multicenter international studies include aspergillosis clinical trial sponsored by Vical (MSG-17) and an endemic mycoses prospective clinical trial cosponsored by the MSG and Mayne (MSG-15). We have several other exciting opportunities in the pipeline.

We are thrilled that the DoctorFungus site is up and running. We welcome contributors, especially “Case of the Month” submissions. The submission process is outlined in the newsletter. The editorial process of updating the hundreds of pages on the site is a monumental task. You can imagine the nomenclature edits that are required! Please visit the site at www.drfungus.org and contribute! We also welcome featuring any educational links here. We continue to link to funguscme.org for important CME enduring offerings.

Finally, we do aim to focus the coming year on putting that FACE on clinical mycology. There are stories behind each of our patients who suffer through these diseases. We aim to give voice to those stories. As you assemble your “cases” for DrFungus.org, consider also adding the patient voice, including the use of multi-media. Let’s share the “Face of Fungal Infection” with those who visit our website This is an important aspect of our overall mission and can also help to drive new product development.

Thank you again for your ongoing support and dedication to our mission. I look for to seeing you at Big Sky in September!

Best,

Peter G. Pappas, MD
MSG STUDIES

MSG-06: The Phaeohyphomycosis Registry
PIs: Sanjay Revanker, John Baddley, Sharon Chen
Sponsors: Merck, Gilead, Astellas
Enrollment began on October 31, 2012 and closed on 12/31/2015. A total of 110 cases were enrolled, and 99 were included as part of the final dataset. The registry includes cases diagnosed between January 1, 2009 and December 31, 2015. Sixteen sites participated and enrolled cases. Sites are located in South America (1), Australia (2), and North America (13). This project prospectively identifies 110 patients from these sites and captures all relevant clinical, diagnostic, mycological and treatment/outcome information relating to this uncommon mycosis. These data will ultimately be merged with relevant data from the ongoing Fungiscope project led by Oliver Cornely in FRG. An important component of this study is that CDC serves as specimen repository for the project, providing access to these clinical specimens by all MSG investigators. The manuscript has been published by OFID. (Revankar SG, Baddley JW, Chen S, Kauffman CA, Slavin M, Vazquez JA, Seas C, Morris ML, Nguyen H, Shoham S, Thompson III GR, Alexander B, Simkins J, Ostrasky-Zeichner L, Mullane K, Alangaden G, Andes DR, Cornely O, Wahlers K, Lockhart S, Pappas PG. A Mycoses Study Group international prospective study of phaeohyphomycosis: an analysis of 99 proven and probable cases)

MSG-07: Cryptococcosis Combined Analyses
PIs: John Baddley, Sharon Chen, Emilio DeBess, Eleni Galanis, Julie Harris, Nicola Marsden-Haug, John Perfect, Peter Phillips, Peter Pappas
Sponsor: Merck
This retrospective study will evaluate archived cases of C. neoformans and C. gattii from UAB, Duke, Australia, BC Canada, Washington, and Oregon. Over 800 well-defined cases have been identified. UAB has obtained signed data use agreements with participating sites and has received data from each site. Data merger is complete. The analysis for the primary manuscript is finalized, and the manuscript is being prepared.

MSG-08: Epidemic Mold Infections in U.S.
PIs: Carol Kauffman, Tom Chiller, Peter Pappas
Sponsors: CDC, Gilead, Merck
MSG received funding from Merck, Gilead, and the CDC to support this project based on capturing the detailed, long-term clinical and therapeutic features of this outbreak. Data points include diagnostic, clinical, radiologic, treatment and outcomes data, and these data have assisted with defining disease management. MSG’s role has included site selection, electronic case report form development, data management and analysis. Nine sites participated with providing case data. Enrollment began in September 2013 and all data collection was complete by February 2016. Final dataset included 456 cases entered in the REDCap electronic database. A primary manuscript is being developed by Anu Malani and Carol Kauffman and will be ready for distribution by the Fall 2018.
**MSG-09: Prospective study of cryptococcosis among non-HIV infected patients**  
**PI:** Kieren Marr, MD  
**Sponsor:** NIAID  
This observational, prospective study started enrollment of patients with cryptococcosis who are HIV negative on March 14, 2014. This study captures all relevant epidemiology, clinical and therapeutic data. In addition, immunologic and genetic studies are being performed on each study participant to explore host response to infection and genetic predispositions to disease expression. Manuscript in preparation.

**MSG-10: A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Estimate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral SCY-078 vs. Standard of Care Following Initial Intravenous Echinocandin Therapy in the Treatment of Invasive Candidiasis (Including Candidemia) in Hospitalized Nonneutropenic Adults**  
**PI:** Andrej Spec, MD, Peter Pappas, MD  
**Sponsor:** Scynexis  
This phase 2 study open-label RCT was completed fall 2016. The primary focus of the trial was safety and PK; efficacy is a secondary endpoint given the small sample size. The trial design focused on a step-down strategy for candidemia. Of 27 enrolled participants, 22 were evaluable. Andrej Spec is writing the primary manuscript. Results were presented at ECCMID 2017.

**MSG-11: Cryptococcal Infections in Non–HIV Infected Hosts: A Prospective International Study**  
**PI:** Peter Pappas, MD  
**Sponsor:** Gilead  
This study is an international observational study, which is similar in design to MSG-09, which was originally proposed as an international study. As an international study, MSG 11 includes sites in Australia, Canada, Taiwan and western Europe. We are also approaching sites in Viet Nam, France, and India. Our goal is to enroll 150 non-HIV infected patients with proven or probable cryptococcosis. Currently there are 35 patients enrolled, it has difficult to find sites, and more difficult than expected to find eligible subjects. Data updates in REDCap in progress.

**MSG-12: Retrospective review of candidemia outcomes in a large US cohort utilizing the Premier database**  
**PI:** Brian Fisher, MD, Theo Zaoutis, MD, Luis Ostrosky-Zeichner, MD  
**Sponsor:** CHOP  
This study was initiated by Drs. Fisher and Zaoutis at CHOP following their purchase of aspects of the Premier database. The purpose of this study is to analyze treatment and outcomes among a large cohort (approximately 2000 patients) across the US with Candida BSI. The first analysis was presented at ICAAC 2015, and has subsequently been published (Chiotos K, Vendetti N, Zaoutis T, Baddley J, Ostrosky-Zeichner L; Pappas PG, Fisher, B. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group [MSG-12] J Antimicrob Chemo 2016; 71: 3536-9.

**PI:** Peter Pappas, MD, Andrej Spec, MD  
**Sponsor:** IMMY  
This pre-510k case-control study to test the IMMY investigational LFA for the diagnose of histoplasmosis was closed on March 13, 2018. Fifteen U.S. sites participated. A total of 28 confirmed histo cases, 23 probable, 49 matched controls, and 66 fungal controls were enrolled. Data management processes to finalize study data and begin analyses are underway.
MSGERC Continuing Education Update

FUNGUSCME.ORG

The MSGERC Education Committee continues to develop live and web-based activities as part of an overall strategic educational plan. We continue to work with Terranova Medica, LLC to develop and manage our CME activity grants. This year, we will launch an online activity entitled “Fungal Frontiers: Expert Decision Making in Medical Mycology,” which features evidence based discussions as well as the opportunity for the learner to benchmark his/her clinical choices against that of experts. We will also feature 2 Mycology Minutes from the 2017 ID meetings TIMM and IDWeek. In the fall of 2018, we will have a symposium at IDWeek on October 4, 2018 starting at 6 pm entitled: Invasive Mold Face-Off: Meeting the Challenge Across the Disease Spectrum. Luis Ostrosky-Zeichner is the chair of the Fungal Frontiers and John Perfect is the chair of the Invasive Mold Face-Off.

Contact Lisa Tushla at ltushla@terranovamedica.com for more information.

The New Antifungal Toolkit 2017: The Pharmacopeia and Beyond

- Originally launched in 2014 and updated through 2017, this is a FREE web-based CME curriculum that provides current information about newer FDA-approved agents/formulations for the management of invasive fungal infections (IFI) and evaluates their role in strategies to optimize antifungal therapy.
- You may start and resume activity
- AMA PRA Category 1 Credits based on number of sections completed
- For further information, contact Tom Davis at tdavis@terranovamedica.com

WWW.DRFUNGUS.ORG

- View the video recordings from mycology’s key opinion leaders from talks given at the 1st Biennial Meeting “Clinical Mycology Today 2016” at http://msgerc.org/Learning-from-the-MSGERC-2016-Biennial-meeting
- Additional educational activities that are planned for Summer/Autumn 2018 include clinical mycology continuing education of rural-based physicians (Talem Health, LLC) and in diagnostics (IMMY) that many of our members are independent consultants with.

GLOBAL CONTINUING EDUCATION

In 2018, the MSGERC is engaged in two educational activities set in low-resource settings.

- Tom Patterson is leading an educational website initiative known as iFocus that is dedicated for physicians practicing in the Middle East with links to and from the MSGERC and DrFungus websites. Specific recorded lectures will be produced by Dr. Patterson and other MSGERC key opinion leaders. This project is sponsored by OTB Life Science & Technology Consultancy in Dubai, UAE.
Carolynn Jones is leading an activity that will be sponsored by Klintec Academy in Mumbai, India to provide 4 supplemental educational modules in clinical research regulatory affairs, bioethics and quality for a workforce development course being led by Klintec. Additional discussions about future clinical trial sites in India will be coupled with this new educational link.

**Upcoming Studies & Advocacy**

**MSG-15**  SUBA- itraconazole versus conventional itraconazole in the treatment of endemic mycoses: An open-label comparative trial.

*PIs*: GR Thompson, Andrej Spec, Peter Pappas  
*Sponsor*: MAYNE  

Since initial discussions between Mayne Pharmaceutica LLC and the MSGERC during the 2016 Clinical Mycology Today meeting in Pacific Grove, CA, a new endemic protocol has emerged. After the lengthy process of protocol development, IND submission, site selection and clinical operations, the new study is set to launch in Summer 2018. The MSG Central Coordinating Center at the University of Alabama at Birmingham is serving as a “sponsor” for this “investigator-initiated IND”. Leading clinical operations for the MSGCCC is Alisa Peinhardt, MSN, RN. This study is set to be launched in “endemic mycoses” sites in the US, Mexico, Panama and Peru.

**MSG-16**  The Natural History of Antifungal Failure in Invasive Candidiasis in the US: A multi-center study (NATURE)

*PI*: Luis Ostrosky-Zeichner, MD  
*Sponsor*: Scynexis  

The study will be managed primarily by University of Texas Health Sciences Center-Houston with some administrative assistance by the MSGERC and is targeted to launch Autumn 2018.

**MSG-17**  A phase 2 study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with AMS, ALL, or Allogeneic Stem Cell Transplant Recipients.

*PI*: Luis Ostrosky-Zeichner, MD  
*Sponsor*: Vical  

The MSGERC convened an advisory panel to assist in the development of this study protocol which is currently launching Summer 2018 and is seeking active sites in the US and Europe. A total of 200 patients will be enrolled. The MSGERC will convene a DRC for evaluation of study data.

"We hope that MSGERC members will consider this study. Though an IV formulation, arrangements for outpatient infusions have been made, so we hope to see success in enrollment." – P. Pappas.

**Future Pipeline**: We have had exciting preliminary conversations with companies interested in a testing a candidemia vaccine in high risk patients, adjunctive immunotherapy for patients with candidemia, treatment of *C. auris* infections, new therapies for cryptococcal meningitis, and treatment for invasive molds. We have also looked at a device that will potentially filter fungal organisms from the spinal fluid for patients suffering from cryptococcal meningitis. A fungal prophylaxis survey will be launched soon to determine treatment patterns in lung transplant and patients suffering from ALL and lymphoma.  

Stay tuned!
2018 BIENNIAL MEETING "CLINICAL MYCOLOGY TODAY"

Clinical Mycology Today

MSGERC 2018
BIENNIAL meeting
September 25-28, 2018
Big Sky Resort, Big Sky, Montana

SAVE THE DATE & MEMBERSHIP

Join Us for the
MSGERC 2018 Biennial Meeting

When: Tuesday, September 25 to Friday, September 28, 2018

Where: Big Sky Resort
Big Sky, Montana USA

Membership:
Join MSGERC for only $100!
Be a part of mycology research, education and scholarship.
Members receive discounts on the 2018 Biennial Meeting registration, and more. Additional information can be found at MSGERC.org.
Also, enjoy the re-launch of the DoctorFungus website at MSGERCDoctorFungus.org.

Peter G. Pappas, MD, FACP
President, MSGERC
headquarters@msgerc.org

REGISTRATION

- MSGERC Members $500 USD
- Non-Members $600 USD
- Current ID Fellow $250 USD
- Registration: https://msgerc.wildapricot.org/event-2812948/Registration

Contact: headquarters@msgerc.org or Barbara Hamschin at 412-343-2235
### Tuesday, September 25, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noon - 5:00 pm</td>
<td>Registration and Welcome Refreshments</td>
</tr>
<tr>
<td>3:00 - 4:45 pm</td>
<td>MSGERC Board of Directors Meeting</td>
</tr>
<tr>
<td>5:00 - 5:15 pm</td>
<td>Welcome Remarks and Introductions – Peter Pappas</td>
</tr>
<tr>
<td>5:15 - 8:00 pm</td>
<td>Dinner and Sponsor Presentations</td>
</tr>
<tr>
<td>8:00 - 8:30 pm</td>
<td>Q &amp; A and Discussion</td>
</tr>
<tr>
<td>8:30 - 9:00 pm</td>
<td>Overview of Wednesday</td>
</tr>
</tbody>
</table>

### Wednesday, September 26, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 - 7:45 am</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>7:45 - 8:00 am</td>
<td>Welcome – Peter Pappas</td>
</tr>
<tr>
<td>8:00 - 10:00 am</td>
<td><strong>Plenary Lectures: Candida</strong></td>
</tr>
<tr>
<td></td>
<td>Facilitators: Luis Ostrosky-Zeichner and Peter Pappas</td>
</tr>
<tr>
<td></td>
<td>• Updates on Candida Immunology: Mihalis Lionakis</td>
</tr>
<tr>
<td></td>
<td>• Antifungal Resistance Among Candida spp: David Perlman</td>
</tr>
<tr>
<td></td>
<td>• What Is New in Epidemiology and C. Auris: Tom Chiller</td>
</tr>
<tr>
<td></td>
<td>• Diagnostics: Neil Clancy</td>
</tr>
<tr>
<td>10:00 - 10:30 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 - 12:30 pm</td>
<td>Candida Facilitated Discussion with Q &amp; A</td>
</tr>
<tr>
<td>12:30 - 1:30 pm</td>
<td>Luncheon and Meet the Fellows</td>
</tr>
<tr>
<td>1:30 - 2:15 pm</td>
<td>Biostatistics for Fungal Disease Trials: Special Considerations - Gerald McGwin</td>
</tr>
<tr>
<td>2:15 - 4:15 pm</td>
<td><strong>Plenary Lectures: Cryptococcus</strong></td>
</tr>
<tr>
<td></td>
<td>Facilitators: John Perfect and David Boulware</td>
</tr>
<tr>
<td></td>
<td>• Host Response/Immunology: Liise-anne Pirofski</td>
</tr>
<tr>
<td></td>
<td>• The Fungus: Andy Alspaugh</td>
</tr>
<tr>
<td></td>
<td>• Treatment Trials in Developing World: David Boulware</td>
</tr>
<tr>
<td></td>
<td>• New Treatments for Cryptococcosis: William Hope</td>
</tr>
<tr>
<td></td>
<td>• Cryptococcal Treatment Guidelines: John Perfect</td>
</tr>
<tr>
<td>4:15 - 4:45 pm</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>4:45 - 6:00 pm</td>
<td>Cryptococcus Facilitated Discussion with Q &amp; A</td>
</tr>
<tr>
<td>6:00 - 7:00 pm</td>
<td>Fellow Poster Sessions/Reception</td>
</tr>
<tr>
<td>7:00 - 8:15 pm</td>
<td>Dinner/Business Meeting and MSGERC Update – Peter Pappas</td>
</tr>
<tr>
<td>8:15 - 9:00 pm</td>
<td>Guest Speaker</td>
</tr>
</tbody>
</table>
Thursday, September 27, 2018

6:45 - 7:45 am  Continental Breakfast
7:45 - 8:00 am  Opening Welcome - Peter Pappas
8:00 - 10:00 am  Plenary Lectures: Aspergillus and Other Moulds

   Facilitators: Dimitrios Kontoyanniann and Marisa Miceli

   • Aspergillus Diagnostics .......................................................... P. Lewis White
   • Prophylaxis and Treatment of IA in 2018............................... Dimitrios Kontoyanniann
   • Insights into Antifungal Resistance, Newer Moulds .................... Nathan Wiederhold
   • What is the Clinical Relevance of Antifungal Resistance? .......... Tom Patterson
     (asp/moulds, New Trials)

10:00 - 10:30 am  Refreshment Break
10:30 - 12:30 pm  Aspergillus and Other Moulds Facilitated Discussion with Q & A
12:30 - 1:30 pm  Luncheon and Meet the Fellows
1:30 - 3:30 pm  Plenary Lectures: Endemic and Other Mycoses

   Facilitators: Andrej Spec and GR Thompson

   • Genetics, Evolutionary Biology, Environment ....................... John Taylor
   • Diagnostics ................................................................. GR Thompson
   • Blastomycoses, Emmonsia ................................................. Ilan Schwartz
   • Histoplasmosis: Latin American Perspective ......................... Ana Belen Arauz

3:30 - 4:00 pm  Break
4:00 - 5:00 pm  Endemic and other Mycoses - Facilitated Discussion with Q & A
5:00 - 7:00 pm  Break
7:00 - 9:30 pm  Working Dinner Session: Facilitator Presentations

Welcome: Peter Pappas

   • Candida .......................................................... Luis Ostrosky-Zeichner and Peter Pappas
   • Cryptococcus .................................................. David Boulware and John Perfect
   • Aspergillus and Other Moulds .................................. Dimitrios Kontoyanniann and Marisa Miceli
   • Endemic and other Mycoses .................................... Andrej Spec and GR Thompson
   • Wrap-Up and Closing Remarks .................................. Peter Pappas

Friday, September 28, 2018

6:30 - 8:30 am  Scientific Committee Debrief Breakfast
**MSGERC Board of Directors (BOD)**
Peter G. Pappas, President  
John Perfect, President Elect  
Luis Ostrosky-Zeichner, Treasurer  
Sharon Chen, Secretary  
Oliver Cornely, Member at Large  
Bart-Jan Kullberg, Member at Large  
Dimitrios Kontoyiannis, Member at Large  
Thomas Patterson, Member at Large  
George Thompson, Member at Large  
Theo Zaoutis, Member at Large  
Tom Chiller, non-voting (CDC)

**Doctor Fungus Advisory Board:**
George Thompson, MD  
Tom Patterson, MD  
Nathan Wiederhold, PhD  
Peter Pappas, MD  
Carol Kauffman, MD  
John Baddley, MD, MPH

**MSG Education Committee**
George R. Thompson (Chair)(US)  
John Baddley (Co-chair) (US)  
Barbara Alexander (US)  
David Andes (US)  
John Bennett (US)  
Helen Boucher (US)  
Oliver Cornely (FRG)  
Graeme Forrest (US)  
Alison Freifeld (US)  
Dimitrios Kontoyiannis (US)  
Bart-Jan Kullberg (NETH)  
Olivier Lortholary (FR)  
Marcio Nucci (BRA)  
Luis Ostrosky-Zeichner (US)  
Peter Pappas (US)  
Tom Patterson (US)  
Monica Slavin (AUS)

**MSGERC Scientific Committee**
Peter G. Pappas, Chair (US)  
David Andes (US)  
David Boulware (US)  
Sharon Chen (AU)  
Oliver Cornely (GR)  
Peter Donnelly (NETH)  
Dimitrios Kontoyiannis (US)  
Bart-Jan Kullberg (NETH)  
Luis Ostrosky-Zeichner (US)  
Kieren Marr (US)  
Tom Patterson (US)  
John Perfect (US)  
Tania Sorrell (AU)  
George Thompson (US)  
Thomas Walsh (US)  
Theo Zaoutis (US)

**Non-Voting SC Advisors:**
John Bennett (US)  
Emilio Bouza (SP)  
Eric Bow (CA)  
Jack Edwards (US)  
Carol Kauffman (US)  
Jack Sobel (US)  
Tania Sorrell (AU)  
John Wingard (US)

**Please follow us on:**
*Twitter*  
@msg_erc  
@DrFungus_MSGERC

**LinkedIn**
Since 1978, the MSG legacy has endured as the clinical and scientific experts in clinical mycology. Once funded by the NIH, this group re-structured in 2014 as an independent non-profit organization. As we planned our inaugural Biennial Meeting, in 2016, we began our formal membership campaign inclusive of a global cohort of investigators, fellows, government agencies and pharmaceutical companies. We encourage you to continue supporting us with your annual formal membership and with our pre-clinical and clinical efforts. Annual dues are $100 per member ($75 for current ID Fellows).

**Official member benefits include:**

1. Recognition as a MSGERC member and the historic value of the group.
2. Identification as a key opinion leader in your mycology specialization.
3. Opportunities to serve as a subcontractor on MSGERC educational endeavors, FUNGUSCME or research advisory boards and DRC members.
4. Recognition as a preferred investigator for mycology clinical research studies.
5. Eligibility to vote on important MSGERC matters that are brought forth to membership.
6. Eligibility to run for MSGERC Board of Directors and hold a leadership position helping to shape the future strategy, goals and mission of our organization.
7. Eligibility to serve as a leader on one of MSGERC’s standing committees.
8. Website presence and DrFungus Case of the Month contributor.
10. Reduced meeting registration rates for the Biennial Meetings.
11. Unparalleled access to a global community network of experts and renowned leaders in the mycology field.
CONTACT US

Mycoses Study Group Education and Research Consortium (MSGERC)

Peter G. Pappas, MD, President, MSGERC
William E. Dismukes Professor of Medicine
Division of Infectious Diseases  University of Alabama at Birmingham (UAB)
1900 University Blvd, THT 229
Birmingham, AL 35294 USA
Email: ppappas@uabmc.edu
Tel: (205) 934-9951
Vicki Noles, Dr. Pappas’ Administrative Assistant
Contact: vnoles@uabmc.edu

Carolynn Thomas Jones, DNP, MSPH, RN, Executive Director
1330 Creekside Glen
Irondale, AL 35210
Email: jones.5342@osu.edu
Tel: (205) 612-0421

MSG Coordinating Center, UAB
Alisa Peinhardt, MEIS, RN, Administrator
Email: apeinhardt@uabmc.edu
Phone: 205-934-9661

MSGERC Association Management & Meeting Planning: Kassalen Meeting & Events, LLC
Manages MSGERC Memberships, Websites, Meetings
Beth Kassalen, President
Barbara Hamschin
Linda Maloney
300 Mt. Lebanon Boulevard, Suite 209B
Pittsburgh, Pennsylvania 15234 USA
Email: headquarters@msgerc.org
Tel: 412-343-2235
Fax: 412-344-0599
www.kassalen.org